20:57 , Aug 15, 2019 |  BC Extra  |  Company News

Harmony crosses finish line with Wakix for narcolepsy

FDA approved Wakix pitolisant Thursday, almost two years after Harmony gained U.S. rights to the narcolepsy drug. During 2017-18, Harmony raised $295 million to push it through registration. In October 2017, Harmony Biosciences LLC (Plymouth...
20:53 , Mar 8, 2019 |  BC Extra  |  Preclinical News

Janssen, Scripps discover small molecule for flu

Janssen and Scripps have generated an oral compound for treating flu that inhibits the HA protein on influenza H1 and H5 strains. Recent studies have led to the development of broadly neutralizing antibodies (bNAbs) that...
00:07 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest modulating SF3B1-mediated splicing alone or in combination with BCL-2 and Bcl-XL inhibitors could help treat MCL1-dependent NSCLC. In three human MCL1-dependent NSCLC cell...
20:21 , Dec 21, 2018 |  BC Week In Review  |  Company News

BMS, H3 Biomedicine evaluate RNA splicing technology

Bristol-Myers Squibb Co. (NYSE:BMY) and Eisai Co. Ltd. (Tokyo:4523), along with its subsidiary H3 Biomedicine, Inc. (Cambridge, Mass.), partnered to use H3’s RNA splicing platform to develop immunotherapies. H3 and BMS will jointly conduct the...
03:19 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
22:38 , Jun 13, 2018 |  BC Extra  |  Company News

Management tracks: Salk Institute, Galectin

The Board of Trustees for the Salk Institute for Biological Studies (La Jolla, Calif.) said that cancer and gene therapy researcher Inder Verma has resigned. The institute had placed Verma on administrative leave in April...
18:58 , May 9, 2018 |  BC Innovations  |  Translation in Brief

Dissecting rare gliomas

In an April Science study, researchers from Massachusetts General Hospital and Harvard Medical School identified a subpopulation of malignant cells driving disease progression in rare pediatric gliomas with mutated histone H3 K27M using single-cell RNA...
22:45 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest CAR T cells targeting GD2 could help treat diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas harboring the H3.3A K27M mutation. In co-culture with...
21:54 , Apr 16, 2018 |  BC Extra  |  Preclinical News

Anti-GD2 CAR T could treat midline gliomas

A study published in Nature Medicine suggests that CAR T cells targeting ganglioside GD2 could help treat diffuse midline gliomas with mutated histone H3 K27M. GD2 has been identified as a target to treat cancers...
19:41 , Mar 8, 2018 |  BC Innovations  |  Emerging Company Profile

Splice time

Skyhawk Therapeutics Inc. is developing small molecules that manipulate the stability of the spliceosome during RNA processing to correct splicing defects that drive disease. Instead of focusing on genes in classic exon-skipping diseases, the newco...